148 related articles for article (PubMed ID: 17692798)
1. Multiple myeloma: lusting for NF-kappaB.
Gilmore TD
Cancer Cell; 2007 Aug; 12(2):95-7. PubMed ID: 17692798
[TBL] [Abstract][Full Text] [Related]
2. NF-κB dysregulation in multiple myeloma.
Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
[TBL] [Abstract][Full Text] [Related]
3. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
4. [Molecular pathogenesis of myeloma for the therapeutic targets].
Hanamura I
Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
[TBL] [Abstract][Full Text] [Related]
5. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
Vrábel D; Pour L; Ševčíková S
Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
[TBL] [Abstract][Full Text] [Related]
6. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
7. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
8. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.
Ang DA; Carter JM; Deka K; Tan JHL; Zhou J; Chen Q; Chng WJ; Harmston N; Li Y
Nat Commun; 2024 Mar; 15(1):2513. PubMed ID: 38514625
[TBL] [Abstract][Full Text] [Related]
9. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
[TBL] [Abstract][Full Text] [Related]
10. PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling.
Zheng P; Guo H; Li G; Han S; Luo F; Liu Y
Biochem Biophys Res Commun; 2015 Mar; 458(2):328-33. PubMed ID: 25656574
[TBL] [Abstract][Full Text] [Related]
11. The kinase NIK as a therapeutic target in multiple myeloma.
Gardam S; Beyaert R
Expert Opin Ther Targets; 2011 Feb; 15(2):207-18. PubMed ID: 21204728
[TBL] [Abstract][Full Text] [Related]
12. Novel c-Myc G4 stabilizer EP12 promotes myeloma cytotoxicity by disturbing NF-κB signaling.
Yao R; Zhang Y; Zeng Y; Zhang Y; Liu L; Gao J
Exp Cell Res; 2023 Oct; 431(1):113759. PubMed ID: 37625768
[TBL] [Abstract][Full Text] [Related]
13. Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway.
Roy P; Mukherjee T; Chatterjee B; Vijayaragavan B; Banoth B; Basak S
Oncogene; 2017 Mar; 36(10):1417-1429. PubMed ID: 27641334
[TBL] [Abstract][Full Text] [Related]
14. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Wang H; Liu X; Xu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):531-7. PubMed ID: 18549623
[TBL] [Abstract][Full Text] [Related]
15. Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.
Harquail J; LeBlanc N; Landry C; Crapoulet N; Robichaud GA
J Mammary Gland Biol Neoplasia; 2018 Sep; 23(3):177-187. PubMed ID: 30032344
[TBL] [Abstract][Full Text] [Related]
16. Effects of lncRNA HOTAIR on proliferation and apoptosis of myeloma cells through NF-κB pathway.
Zhu BZ; Lin L
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10042-10048. PubMed ID: 31799674
[TBL] [Abstract][Full Text] [Related]
17. Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma.
Zaravinos A; Kanellou P; Lambrou GI; Spandidos DA
Tumour Biol; 2014 May; 35(5):4987-5005. PubMed ID: 24481661
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.
Nagel D; Vincendeau M; Eitelhuber AC; Krappmann D
Oncogene; 2014 Dec; 33(50):5655-65. PubMed ID: 24469030
[TBL] [Abstract][Full Text] [Related]
19. Gene mutation revelation points to new target for myeloma treatment, studies say.
Garber K
J Natl Cancer Inst; 2007 Sep; 99(18):1362-4. PubMed ID: 17848662
[No Abstract] [Full Text] [Related]
20. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
